12-01 :: January 2012
he Board of Directors of AMCOL International Corporation (NYSE: ACO) has appointed Pa-
trick Carpenter as President of AMCOL‘s Environ- mental segment. Mr. Carpenter has been with the company for 20 years working within management roles for the Building Materials and Lining Technolo- gies businesses.
For the fourth quarter of 2011, AMCOL Internati- onal Corporation (NYSE: ACO) generated diluted earnings per share attributable to its shareholders from continuing operations of $0.43 per share versus a loss of $0.30 per share in the prior year‘s quarter. Excluding unusual items in Q4 2010, diluted ear- nings per share attributable to our shareholders was $0.21 per diluted share. Net sales increased 6.5% to $233.7 million for the 2011 fourth quarter, as com- pared to $219.4 million for the 2010 period. Gross profit increased 16.1% while gross margin increased 220 basis points to 26.6%. Operating profit increa- sed 63.8% with operating margin increasing by 300 basis points to 8.6%.
the Company’s workforce, right size capacity, and reduce operating costs in 2012. In addition, the Company will be terminating the lease of one of its U.S. facilities, which will result in a reduction in annual operating expenses related to this facility. AMRI expects that these cost-reduction initiatives will result in annual savings of approximately $10-11 million, including $7 million relating to the previous- ly announced cessation of R&D activities, and that
MRI (NASDAQ: AMRI) announced actions taken in the fourth quarter of 2011 to reduce
these savings will begin to be recognized in the first quarter of 2012.
Canadian Government to provide secure commu- nication systems that will be used to satisfy mobile application security requirements. The order was awarded to EMCON Emanation Control, part of API’s Secure Systems & Information Assurance (SSIA) division.
(NASDAQ: ALNY), a leading RNAi therapeutics com- pany, and a nanomedicine company with develop- ment programs in RNAi and obesity, have entered into a collaboration and joint licensing agreement. Alnylam has granted Arrowhead a license under its intellectual property that enables the discovery, de- velopment, and commercialization of an RNAi thera- peutic targeting the hepatitis B virus (HBV). Alnylam is eligible to receive from Arrowhead milestone payments and royalties on sales of product resulting from the license. In addition, Alnylam has received a license from Arrowhead to utilize their Dynamic Polyconjugate (DPC) delivery technology for an RNAi therapeutic product. Alnylam expects to deploy this technology for an undisclosed target in its “Alnylam 5x15” pipeline which is focused on genetically de- fined targets and diseases. Arrowhead is eligible to
rrowhead Research Corporation, (NASDAQ: ARWR) and Alnylam Pharmaceuticals, Inc.
PI Technologies Corp. (NASDAQ: ATNY) has received a $3.5 million new order from the